{"nctId":"NCT00307164","briefTitle":"Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy","startDateStruct":{"date":"2006-09"},"conditions":["HIV Infections","Lipoatrophy"],"count":167,"armGroups":[{"label":"NucleomaxX","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: NucleomaxX"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: NucleomaxX placebo"]}],"interventions":[{"name":"NucleomaxX","otherNames":[]},{"name":"NucleomaxX placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* HIV-1 infected\n* Stable ART containing zidovudine or stavudine for at least 12 consecutive weeks prior to study entry\n* Cumulative ART with zidovudine or stavudine for at least 24 weeks prior to study entry\n* Viral load of 5,000 copies/ml or less within 45 days prior to study entry\n* Lipoatrophy in at least two of the following areas: face, arms, legs, OR buttocks\n* Not planning to add to or change current vitamin supplementation\n* Willing to use acceptable forms of contraception\n\nExclusion Criteria:\n\n* Life expectancy of less than 12 months\n* Currently enrolled in or planning to enroll in an ART interruption study\n* Plans to change current ART regimen\n* Liver failure at anytime prior to study entry\n* Greater than Grade 2 diarrhea or vomiting within 7 days prior to study entry\n* Current AIDS-defining opportunistic infection or illness. Individuals with cutaneous Kaposi's sarcoma not requiring chemotherapy are not excluded.\n* Currently receiving insulin or oral hypoglycemic products for diabetes mellitus\n* Systemic cancer chemotherapy or immunomodulating agents within 30 days prior to study entry\n* Systemic steroids for a cumulative duration of longer than 4 weeks within the 6 months prior to study entry\n* Known allergy or sensitivity to study drug or any of its components\n* Severe lactose intolerance\n* Current drug or alcohol abuse or dependence\n* Clinically significant illness requiring systemic treatment or hospitalization\n* Chronic disability or serious illness that may affect body composition\n* Received an investigational drug other than NucleomaxX or uridine for lipoatrophy within 30 days prior to study entry\n* Certain abnormal laboratory values\n* Pregnancy or breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Limb Fat (g) From Baseline","description":"Limb fat was measured at baseline and visit week 48 using dual-energy x-ray absorptiometry (DEXA), and change from baseline to week 48 (week 48 - baseline) was estimated for the treatment groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Safety Events (Signs/Symptoms or Laboratory Abnormalities)","description":"Time to safety events (grade 3 \\[Severe\\] or 4 \\[life-threatening\\] sign/symptom or laboratory-based abnormality that is at least one grade higher than baseline) from study entry","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.1","spread":null},{"groupId":"OG001","value":"47.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Discontinuing Study Medication","description":"Number of eligible subjects who discontinued study medication during the study period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Limb Fat From Baseline (Week 24 - Baseline)","description":"Limb fat was measured at baseline and visit week 24 using dual-energy x-ray absorptiometry (DEXA), and change from baseline to week 24 (week 24 - baseline) was estimated for the treatment groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"HIV-1 RNA Level","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in CD4+ Count From Baseline (Week 48 - Baseline)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Lactate From Baseline (Week 48 - Baseline)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Glucose From Baseline (Week 48 - Baseline)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Total Cholesterol From Baseline (Week 48 - Baseline)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"-6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting High-density Lipoprotein (HDL) Cholesterol From Baseline (Week 48 - Baseline)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"-1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Non-HDL Cholesterol From Baseline (Week 48 - Baseline)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Low-density Lipoprotein (LDL) Cholesterol From Baseline (Week 48 - Baseline)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"-3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Triglycerides From Baseline (Week 48 - Baseline)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Hemoglobin From Baseline (Week 48 - Baseline)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Leukocytes From Baseline (Week 48 - Baseline)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Creatine Kinase From Baseline (Week 48 - Baseline)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":83},"commonTop":["Blood cholesterol abnormal","Neuropathy peripheral","Blood glucose abnormal","Low density lipoprotein abnormal","Blood creatine phosphokinase increased"]}}}